Skip to Main Content
Wexler Boley & Elgersma LLP
  • Our Firm
    • Who We Serve
      • Shareholders
      • Whistleblowers
      • Consumers
      • Businesses
      • Government Entities
    • Our Professionals
    • Working with Wexler Boley & Elgersma LLP
    • Locations
    • News
    • Careers
    • Report Your Concern
    • Testimonials
  • Practice Areas
    • Antitrust Litigation
    • Business & Commercial Litigation
    • Securities & Corporate Governance
    • Healthcare Litigation
    • Consumer Protection
    • Whistle Blower False Claims Litigation
    • Government Representation
    • Employment Litigation
  • Cases
    • Antitrust Litigation Cases
    • Business & Commercial Litigation Cases
    • Consumer Protection Cases
    • Employment Litigation Cases
    • Government Representation Cases
    • Healthcare Litigation Cases
    • Mass Tort Litigation Cases
    • Securities & Corporate Governance Cases
    • Whistle Blower False Claims Cases
  • Investigations
    • Similac Toxic Infant Formula Lawsuit
    • Kid’s Castle Biometric Privacy Lawsuit
    • Contaminated Baby Food Lawsuit
    • Fatal Sportmix Pet Food Recall Class Action Lawsuit
    • Claire’s Data Breach Lawsuit
    • Insurance Denial for Mental Health and Substance Abuse Treatment
    • Perpetual Sales Litigation
    • Railroad Price-Fixing Lawsuit
    • Medicare Advantage Fraud Litigation
    • Biometric Fingerprinting Litigation
  • Blog
  • Contact Us
See all news
12.22.2011

Wexler Wallace Files Case Against Wyeth for Effexor XR

Wexler Wallace LLP, with co-counsel Branstetter Stranch & Jennings, PLLC, and Trujillo Rodriguez and Richards, LLC, filed a case against Wyeth, Inc. on behalf of Indirect Purchasers of the antidepressant Effexor XR. The plaintiffs allege that Wyeth fraudulently obtained a number of method of use patents for Effexor XR and engaged in sham litigation against 16 potential generic competitors in an effort to protect the Effexor XR monopoly.

As part of the scheme, plaintiffs also allege that Wyeth entered into an anticompetitive settlement with the first generic ANDA filer, Teva.  As a result of these actions, generic Effexor XR competition was delayed for more than 2 years.  For a copy of the consolidated complaint, click here.

On December 14, 2011, Kenneth A. Wexler was appointed interim class counsel for the End-Payor class, along with Jeffrey L. Kodroff of Spector Roseman Kodroff & Willis P.C., James E. Cecchi of Carella Byrene Cecchi Olstein Brody & Agnello, P.C., Michael M. Buchman of Pomerantz Haudek Grossman & Gross LLP, Richard J. Burke of Freed & Weiss LLC, and James R. Dugan, II, of The Dugan Law Firm.  Lisa J. Rodriguez of Trujillo Rodriguez & Richards, LLC, was appointed Liaison Counsel for the putative class.  For a copy of the Court’s Order appointing Wexler Wallace LLP as interim class counsel, click here.

Share

  • Facebook
  • Twitter
  • LinkedIn
Image

311 S. Wacker Drive,
Suite 5450
Chicago, IL 60606
P_312.346.2222
F_312.346.0022

  • Our Firm
  • Practice Areas
  • Cases
  • Investigations
  • Newsroom
  • Blog
  • Contact Us
  • Sitemap
  • Privacy Statement
  • Legal Disclaimer

2022 © Wexler Boley & Elgersma LLP